Acadia Pharmaceuticals | ACAD - Loan Capital


Acadia Pharmaceuticals reported $0 in Loan Capital for its fiscal quarter ending in March of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 285.82M 639K Sep/2024
Alnylam Pharmaceuticals USD 1.04B 13.75M Sep/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 596.66M 501K Sep/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Cytokinetics USD 158.75M 554.3M Sep/2025
Eisai JPY 134.75B 34.91B Sep/2025
Eli Lilly USD 40.87B 6.69B Sep/2025
Incyte USD 35.37M 3.61M Sep/2025
J&J USD 39.41B 173M Sep/2025
Moderna USD 26M 6M Sep/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pfizer USD 57.41B 93M Sep/2025
Prothena USD 0 0 Dec/2024
PTC Therapeutics USD 1.84B 298.68M Sep/2025
Sarepta Therapeutics USD 1.04B 104.31M Sep/2025
Ultragenyx Pharmaceutical USD 782.75M 11.3M Jun/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025